Skip to main content
Premium Trial:

Request an Annual Quote

We Get in Your Face

Premium

I congratulate you for the excellent job of publishing an informative and accurate article on genomics grids (“Getting to Genomics ‘Grid Nirvana,’” April 2003). In an area filled with hyperbole and marketing sales pitches, you struck a reasonable balance in illustrating the visionary, unrealized aspects of grid technology when contrasted with the reality of the uses to which grids are currently being used for the processing of genomic information. I feel that the article will genuinely help both the technical and non-technical person to understand the issues associated with the utilization of grid technology.

It is clear that your organization invested a large amount of time and resources in researching, writing, and producing such a well-rounded article.

I risked being very open with Aaron Sender and I am pleased that you folks dealt fairly with the topic matter. Please, feel free to contact me in the future on this or other topic areas.

Doug Brown, Center for Integrated Fungal Research, NC State University

 

I wanted to congratulate you on a great article on grid computing. I am happy for how it turned out, and to have been some help to you in it.

Thanks again for the great article, and for your continued interest!

Ernest F. Retzel, Director, Center for Computational Genomics and Bioinformatics, University of Minnesota

 

Nat Goodman’s article “Microarrays: Hazardous to Your Science,” April 2003, is excellent food for thought.

I must say I am impressed with [your] publication, as one of my colleagues gave me his copy this morning. The style is refreshing. GT seems to “get in the face” of science in that there is as much myth as fact in data generated by “technologists.” Or to put it another way: “it’s about time one calls a spade a spade.” Good work. I am a firm believer that controversy or healthy, objective discussion of the issues is fuel for innovation and scientific improvement.

Keep up the good work.

Mike Crawford, High Throughput Genomics

I find it astounding that you would publish an interview with Andrew Carr, president of Amersham Biosciences (“Carr Goes for Fuel Efficiency,” March 2003), in which he touts the very technology that he and his managers gutted a few weeks before — namely, DNA sequencing/genomics. Carr is now left to manage a very weakened portfolio of discovery products with nothing in the pipeline. This is more like “running on empty” than “fuel efficiency.”

Parke Flick, PhD

 

Editor’s note:

GT’s press deadline is one month in advance of the print date; the March issue went to the printer on February 7. Amersham announced its reorganization on February 27. Considering that Carr agreed to spend an hour in his office with GT on January 23 and gave no hint at that time of any impending organizational changes, our impression is that he was as blindsided by the reorganization as we were.

 

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.